Cobolimab
- Generic Name
- Cobolimab
- Drug Type
- Biotech
- CAS Number
- 2022215-65-0
- Unique Ingredient Identifier
- 3K5H4TX2KP
- Background
Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
Novartis Discontinues Phase 3 Trial of Sabatolimab for Myelodysplastic Syndromes
Novartis has halted the phase 3 STIMULUS-MDS2 trial of sabatolimab, a Tim3-targeting drug, for treating myelodysplastic syndromes (MDS) due to not meeting its primary endpoint. The decision reflects a strategic shift to prioritize other projects within Novartis' portfolio. This development marks a significant setback in the race to bring a Tim3-targeting therapy to market, amidst broader challenges in the field.
Arvinas Advances Vepdegestrant into Phase 3 Trials for Breast Cancer and Updates Pipeline Milestones
• Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
• Topline data from the Phase 3 VERITAC-2 monotherapy trial of vepdegestrant in second-line-plus ER+/HER2- metastatic breast cancer is anticipated in the first quarter of 2025.
• Arvinas is set to present initial data from the Phase 1 trial of ARV-393 in B-cell lymphomas and file an IND application for a novel PROTAC KRAS G12D degrader in 2025.
• Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease has been initiated, with data expected to be presented in the first half of 2025.
AnaptysBio's ANB032 Fails to Meet Endpoints in Phase 2b Atopic Dermatitis Trial
• AnaptysBio's ANB032, a BTLA agonist, did not meet primary or secondary endpoints in a Phase 2b trial for moderate-to-severe atopic dermatitis.
• The ARISE-AD trial included 201 patients and assessed the efficacy of ANB032 as a monotherapy, with no significant improvements observed.
• Despite the drug's failure to meet efficacy endpoints, ANB032 was well-tolerated across all doses, with no significant safety signals reported.
• AnaptysBio will discontinue further investment in ANB032 and shift focus to other assets, including rosnilimab for rheumatoid arthritis and ulcerative colitis.
AnaptysBio Reports Financial Growth and Clinical Trial Progress in Q3 2024
• AnaptysBio's collaboration revenue significantly increased to $30.0 million in Q3 2024, compared to $3.3 million in the same period of 2023, driven by strategic partnerships.
• The company's clinical pipeline advances with rosnilimab in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032 in Phase 2b for atopic dermatitis.
• AnaptysBio anticipates key data readouts, including top-line results from the rosnilimab rheumatoid arthritis trial in February 2025 and ANB032 atopic dermatitis trial in December 2024.
• A new BDCA2 modulator antibody, ANB101, is set to begin Phase 1 clinical trials in Q1 2025, expanding AnaptysBio's focus on autoimmune and inflammatory diseases.
AnaptysBio Announces Upcoming Phase 2b Data for ANB032 in Atopic Dermatitis and Rosnilimab in Rheumatoid Arthritis
• AnaptysBio anticipates top-line Phase 2b data for ANB032, a BTLA agonist, in atopic dermatitis in December 2024, assessing its efficacy and safety over 14 weeks.
• Rosnilimab, a PD-1 agonist, is expected to have top-line Phase 2b data in rheumatoid arthritis in February 2025, following a 12-week placebo-controlled trial.
• A Phase 1 trial has been initiated for ANB033, an anti-CD122 antagonist, in healthy volunteers, with the Phase 1b indication to be disclosed in 2025.
• The company reiterates its cash runway through year-end 2026, ensuring continued funding for its clinical programs.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath